Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
RetiPharma IVS
IVS
In liquidation
Reklamebeskyttelse
CVR 37134120
Ole Maaløes Vej 3, 2200
København N
Engineering activities and related technical consultancy
·
NACE 7112
Est. 2015 · 10 years old
3 employees
Overvåg
Share
Denmark
/
Companies
/
Engineering activities and related technical consultancy
/
RetiPharma IVS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Ledelse
Aktivt ansatte i selskabet
Name
Role
Member since
Former (3)
AR
Anders Rubinstein
Unofficial title
Unofficial title
2019 – 2020
HV
Henrik Vissing
Chief Executive Officer
Chief Executive Officer
2018 – 2019
LH
Line Hartvig
Chief Executive Officer
Chief Executive Officer
2019 – 2019
Bestyrelse
Ikke-udøvende tilsyn
Name
Role
Member since
Former (3)
JA
Jørgen Axel Thorball
Board of Directors
Board of Directors
2018 – 2019
MA
Morten Albrechtsen
Chairman
Chairman
2018 – 2019
CT
Casper Tind Hansen
Board of Directors
Board of Directors
2018 – 2019
Aktionærer
Pr. seneste årsrapport
Shareholder
Type
Ownership
Votes
Since
Anders Tolstrup Christiansen
Individual
5–9.99%
5–9.99%
2015
Casper René Mahajan Gøtzsche
Individual
20–24.99%
20–24.99%
2015
David Paul Drucker Woldbye
Individual
20–24.99%
20–24.99%
2015
WEXOTEC ApS
Company
10–14.99%
10–14.99%
2015
Kristian Klemp
Individual
20–24.99%
20–24.99%
2015
Andreas Toft Sørensen
Individual
5–9.99%
5–9.99%
2018
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on RetiPharma IVS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network